Efficacy of Nebulised Tobramycin in Cystic Fibrosis Management: A Systematic Review

Abstract

Cystic Fibrosis (CF) is a progressive clinical condition associated with decreased functionality of glands that produce mucus, sweat, and intestinal secretions. CF is one of the most common recessive genetic diseases that affect all ethnic groups without any known identified cure, having variations in the severity of symptoms. In the treatment and management of CF, The choice and routes of administration of antibiotics taken is important in assessing effectiveness at different populations. In the light of this, current study was undertaken to determine the efficacy of Nebulised Tobramycin (NT) in the treatment of mild to moderate CF within 8years study period. Study was achieved by searching known repositories and electronic databases of various sources. Randomized Clinical Trials (RCTs) that compares patients treated on NT and placebo were selected, including six (6) RCTs comprising 609 participants to the review. Study noticed significant clinical and methodological heterogeneity among trials with NT, varying over a total of 8years study period. Also, there were recorded evidences of improvement in pulmonary function in most of the patients, following completion of the study. This review revealed inconclusive evidence in the efficacy of NT in the treatment of mild to moderate CF. It is thus clear, that long term use of NT in mild to moderate CF can provide sustained improvements in pulmonary functions.